CIK 0001661998 · Non-accelerated filer<br>Smaller reporting company
Q32 Bio Inc.
Sign in to watch- Ticker
- QTTB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473468154
- Phone
- 781-999-0232
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Former names
- Q32 Bio Inc., Homology Medicines, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $320,396
- in 6 filings
Net −$320,396. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-24 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +2,880 | 2,880 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Returned to the company · Stock Option (Right to Buy) | −12,767 | 0 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +12,767 | 12,767 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Returned to the company · Stock Option (Right to Buy) | −1,316 | 0 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Returned to the company · Stock Option (Right to Buy) | −23,140 | 0 | ||
| 2025-02-24 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +23,140 | 23,140 | ||
| 2025-01-15 | Manke Isaac Director | Grant or award · Stock Option (Right to Buy) | +19,008 | 19,008 | ||
| 2025-01-15 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +18,595 | 18,595 | ||
| 2025-01-15 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +23,140 | 23,140 | ||
| 2024-10-15 | Violette Shelia M. Chief Scientific Officer | Option exercise | +6,000 | $7.29 | $44K | 23,874 |
| 2024-10-15 | Violette Shelia M. Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −6,000 | 32,891 | ||
| 2024-10-11 | Violette Shelia M. Chief Scientific Officer | Option exercise | +4,574 | $3.12 | $14K | 17,874 |
| 2024-10-11 | Violette Shelia M. Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −213 | 0 | ||
| 2024-10-11 | Violette Shelia M. Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −4,361 | 0 | ||
| 2024-10-08 | Violette Shelia M. Chief Scientific Officer | Option exercise | +13,300 | $3.12 | $41K | 13,300 |
| 2024-10-08 | Violette Shelia M. Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) | −13,300 | 213 | ||
| 2024-09-25 | Lundberg Sven Ante Director | Grant or award · Stock Option (Right to Buy) | +1,316 | 1,316 | ||
| 2024-04-01 | Manke Isaac Director | Grant or award · Stock Option (Right to Buy) | +2,627 | $13.42 | $35K | 2,627 |
| 2024-04-01 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +2,569 | $13.42 | $34K | 2,569 |
| 2024-03-25 | TZIANABOS ARTHUR Director | Option exercise | +1,095 | 8,248 |
Page 7 of 11 · 207 trades